The UK and US have agreed to a major trade agreement that will keep no duties on British drug products entering the American market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has agreed to increase funding on pharmaceuticals through the public health system. This move secures that import taxes on these vital exports will stay at nothing for a duration of 36 months.
This deal follows recent threats to significantly raise import taxes on branded drug imports, with figures floated as high as 100%.
"This agreement with the United Kingdom strengthens the worldwide climate for cutting-edge drugs and introduces long-overdue balance to transatlantic drug exports," a statement said.
Economic Significance
Pharmaceuticals constitute one of the UK's biggest goods shipped to the United States, which is clearly the biggest market for large UK drugmakers.
Statistics indicate that in the year leading up to the third quarter, the UK sold medicines totaling over eleven billion pounds to the US. This value made up a significant portion of all goods exports in that timeframe.
"This agreement secures employment, stimulates funding and facilitates the UK to become a international leader for medical research," a minister commented.
Key British Pledges
The deal involves several key changes from the United Kingdom:
- Price Threshold Increase: The UK will increase the price threshold at which it deems new medicines to be prohibitively costly by 25%.
- Increased NHS Spending: There is a goal to double total NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Payback Limit: The percentage manufacturers must pay back to the NHS to prevent overspending will be capped at fifteen percent. Last year, refunds topped twenty percent.
Industry Background
This agreement takes place against a ongoing row between the pharmaceutical industry and the UK government over medicine costs and NHS adoption.
The disagreement were exacerbated by arguments that US customers were paying several times more for the identical medicines than people in the UK and Europe.
Recently, several significant pharmaceutical investments in the UK have been delayed or abandoned, while major funding commitments have been directed toward American operations.
A senior figure publicly accepted that the NHS had to increase expenditure on treatments, noting that its spending on drugs had decreased as a proportion of its resources over the past decade.
